Free Newsletter
Stimulus bill provides source of new R&D funds
The Senate is expected to push through a revised stimulus bill that includes $17.8 billion for biomedical research and development, according to a report in New Scientist. The research community is likely to prefer it over the House version of stimulus economics, where lawmakers penciled in $13.2 billion for R&D.
The NIH is slated to get much of the new money, with the Senate designating $6.5 billion for the federal research group. The National Science Foundation is slated to receive $1.2 billion under the Senate version and $3 billion in the House bill. Whatever House and Senate lawmakers pass will have to be reconciled in committee before a final bill heads to the president. Obama has made the stimulus effort the top initial goal of the new administration.
The research community has complained loud and long about the Bush administration's decision to keep new R&D spending flat for the past five years. New R&D money, critics maintained, was badly needed to provide grants to the nation's young scientists, who in turn could hire an up-and-coming generation of students for their lab work.
- read the report from New Scientist
Related Articles:
Biotech leaders to ask Congress for bailout
Economic crisis hammers small, mid-sized biotechs
Credit crisis pushes biotechs to the brink
Report warns of consequences of flat NIH funding
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




